Browse studies

Find your next paid study

101 recruiting studies matching your filters

Understanding the Metabolic Pathology of Pediatric Obesity and NAFLD

Nonalcoholic fatty liver disease (NAFLD) is now the most common liver disease worldwide and affects nearly 40% of obese youth and up to 10% of the general pedi…

Nonalcoholic Fatty LiverNonalcoholic SteatohepatitisObesity

Estimated

~$10 – $6,250

University of OklahomaNCT05430178

Phase 1

Fecal Microbiome Changes Characterization and Safety Evaluation After Oral Administration of Lyophilized Capsules Containing Microbiota Suspension in Severe Alcoholic Hepatitis Patients: Double Blinded, Randomized, Placebo-Controlled Study.

This is a single center, randomized, parallel assignment, and double-blind placebo-controlled pilot study to characterize the intestinal microbiome in patients…

Alcoholic Hepatitis

Estimated

~$10 – $7,500

Prasun Kumar JalalNCT05006430

Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 1

This study is being done to better understand the relationship between inflammation in adipose tissue (AT), abnormal deposition of fat around the liver and how…

Obesity, MorbidNASH - Nonalcoholic SteatohepatitisChronic Inflammation

Estimated

~$10 – $750

Mayo ClinicNCT04232566

Observational

Evaluation of a Persuasive Health Communication Intervention Designed to Increase HIV/HCV Screening Among Emergency Departments Patients Who Currently, Formerly or Never Injected Drugs.

A major impediment to emergency department (ED)-based HIV/HCV screening success is that often ED patients at risk for, or later diagnosed with, HIV and HCV dec…

Human Immunodeficiency Virus (HIV)Hepatitis C (HCV)

Estimated

~$10 – $6,250

University of South FloridaNCT05968573

Phase 4

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cir…

Hepatitis BCirrhosis, LiverChronic Liver Disease

Estimated

~$10 – $6,250

Mercy Medical CenterNCT04588077